Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arfolitixorin vs Calciumfolinate with 5-FU in CRC Liver Metastases
NCT04126655Phase 2Unknown
- Sponsor
- Region Västra Götaland
- Start
- Feb 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of arfolitixorin in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Region Västra Götaland. Primary endpoints: Thymidylate synthase inhibition in tumor tissue, Thymidylate synthase inhibition in adjacent liver parenchyma and 1 more. Status: unknown.
02
Drugs
arfolitixorin
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04126655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126655.